Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 4/2019

01-08-2019 | ORIGINAL ARTICLE

The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury

Authors: Vince Siebert, Joseph Allencherril, Yumei Ye, Xander H. T. Wehrens, Yochai Birnbaum

Published in: Cardiovascular Drugs and Therapy | Issue 4/2019

Login to get access

Abstract

MicroRNAs (miRNA) are non-coding RNAs that regulate gene expression in up to 90% of the human genome through interactions with messenger RNA (mRNA). The expression of miRNAs varies and changes in diseased and healthy states, including all stages of myocardial ischemia-reperfusion and subsequent ischemia-reperfusion injury (IRI). These changes in expression make miRNAs an attractive potential therapeutic target. Herein, we review the differences in miRNA expression prior to ischemia (including remote ischemic conditioning and ischemic pre-conditioning), the changes during ischemia-reperfusion, and the changes in miRNA expression after IRI, with an emphasis on inflammatory and fibrotic pathways. Additionally, we review the effects of manipulating the levels of certain miRNAs on changes in infarct size, inflammation, remodeling, angiogenesis, and cardiac function after either ischemia-reperfusion or permanent coronary ligation. Levels of target miRNA can be increased using molecular mimics (“agomirs”), or can be decreased by using “antagomirs” which are antisense molecules that act to bind and thus inactivate the target miRNA sequence. Other non-coding RNAs, including long non-coding RNAs and circular RNAs, also regulate gene expression and have a role in the regulation of IRI pathways. We review the mechanisms and downstream effects of the miRNAs that have been studied as therapy in both permanent coronary ligation and ischemia-reperfusion models.
Literature
1.
Altesha M-A, Ni T, Khan A, Liu K, Zheng X. Circular RNA in cardiovascular disease. J Cell Physiol. 2019;234:5588–600.CrossRefPubMed
2.
Bayoumi AS, Teoh J-P, Aonuma T, Yuan Z, Ruan X, Tang Y, et al. MicroRNA-532 protects the heart in acute myocardial infarction, and represses prss23, a positive regulator of endothelial-to-mesenchymal transition. Cardiovasc Res. 2017;113:1603–14.CrossRefPubMedPubMedCentral
3.
Bellera N, Barba I, Rodriguez-Sinovas A, Ferret E, Asín MA, Gonzalez-Alujas M, et al. Single intracoronary injection of encapsulated Antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling. J Am Heart Assoc. 2014;3:e000946.CrossRefPubMedPubMedCentral
4.
Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science (80- ). 2009;324:1710–3.CrossRef
5.
6.
Briceno N, Schuster A, Lumley M, Perera D. Ischaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation. Heart. 2016;102:397–406.CrossRefPubMed
7.
Bromage DI, Pickard JMJ, Rossello X, Ziff OJ, Burke N, Yellon DM, et al. Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovasc Res. 2016;113:cvw219.CrossRef
8.
Campani V, De Rosa G, Misso G, Zarone MR, Grimaldi A. Lipid nanoparticles to deliver miRNA in cancer. Curr Pharm Biotechnol. 2016;17:741–9.CrossRefPubMed
9.
Chen Z, Qi Y, Gao C. Cardiac myocyte-protective effect of microRNA-22 during ischemia and reperfusion through disrupting the caveolin-3/eNOS signaling. Int J Clin Exp Pathol. 2015;8:4614–26.PubMedPubMedCentral
10.
Chen C, Ponnusamy M, Liu C, Gao J, Wang K, Li P. MicroRNA as a therapeutic target in cardiac remodeling. Biomed Res Int. 2017;2017:1–25.
11.
Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X, et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res. 2010;87:431–9.CrossRefPubMedPubMedCentral
12.
13.
Cong B-H, Zhu X-Y, Ni X. The roles of microRNA-22 in myocardial infarction. Sheng Li Xue Bao. 2017;69:571–8.PubMed
14.
Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem. 2009;284:29514–25.CrossRefPubMedPubMedCentral
15.
Dutka M, Bobiński R, Korbecki J. The relevance of microRNA in post-infarction left ventricular remodelling and heart failure. Heart Fail Rev. 2019;24:575–86.CrossRefPubMedPubMedCentral
16.
17.
Fan X, Weng X, Zhao Y, Chen W, Gan T, Xu D. Circular RNAs in cardiovascular disease: An overview. Biomed Res Int. 2017;2017:1–9.
18.
Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS One. 2014;9:e88685.CrossRefPubMedPubMedCentral
19.
Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011;124:720–30.CrossRefPubMed
20.
21.
Garikipati VNS, Verma SK, Jolardarashi D, Cheng Z, Ibetti J, Cimini M, et al. Therapeutic inhibition of miR-375 attenuates post-myocardial infarction inflammatory response and left ventricular dysfunction via PDK-1-AKT signalling axis. Cardiovasc Res. 2017;113:938–49.CrossRefPubMed
22.
Ge Z-W, Zhu X-L, Wang B-C, Hu J-L, Sun J-J, Wang S, et al. MicroRNA-26b relieves inflammatory response and myocardial remodeling of mice with myocardial infarction by suppression of MAPK pathway through binding to PTGS2. Int J Cardiol. 2019;280:152–9.CrossRefPubMed
23.
Geng H-H, Li R, Su Y-M, Xiao J, Pan M, Cai X-X, et al. The circular RNA Cdr1as promotes myocardial infarction by mediating the regulation of miR-7a on its target genes expression. PLoS One. 2016;11:e0151753.CrossRefPubMedPubMedCentral
24.
Gottlieb RA, Pourpirali S. Lost in translation: miRNAs and mRNAs in ischemic preconditioning and ischemia/reperfusion injury. J Mol Cell Cardiol. 2016;95:70–7.CrossRefPubMed
25.
Guo Y, Luo F, Liu Q, Xu D. Regulatory non-coding RNAs in acute myocardial infarction. J Cell Mol Med. 2017;21:1013–23.CrossRefPubMed
26.
27.
He B, Xiao J, Ren A, Zhang Y, Zhang H, Chen M, et al. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. J Biomed Sci. 2011;18:1–10.CrossRef
28.
He Q, Wang F, Honda T, James J, Li J, Redington A. Loss of miR-144 signaling interrupts extracellular matrix remodeling after myocardial infarction leading to worsened cardiac function. Sci Rep. 2018;8:16886.CrossRefPubMedPubMedCentral
29.
Hinkel R, Penzkofer D, Zühlke S, Fischer A, Husada W, Xu Q-F, et al. Inhibition of MicroRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128:1066–75.CrossRefPubMed
30.
Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation. 2010;122:S124–31.CrossRefPubMedPubMedCentral
31.
Hu J, Huang C-X, Rao P-P, Zhou J-P, Wang X, Tang L, et al. Inhibition of microRNA-155 attenuates sympathetic neural remodeling following myocardial infarction via reducing M1 macrophage polarization and inflammatory responses in mice. Eur J Pharmacol. 2019;851:122–32.CrossRefPubMed
32.
Huang Y, Qi Y, Du J-Q, Zhang D. MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4. Expert Opin Ther Targets. 2014;12:1355–65.
33.
Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res. 2012;110:71–81.CrossRefPubMed
34.
Icli B, Wara AKM, Moslehi J, Sun X, Plovie E, Cahill M, et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res. 2013;113:1231–41.CrossRefPubMedPubMedCentral
35.
Kamps JA, Krenning G. Micromanaging cardiac regeneration: targeted delivery of microRNAs for cardiac repair and regeneration. World J Cardiol. 2016;8:163.CrossRefPubMedPubMedCentral
36.
Li J, Rohailla S, Gelber N, Rutka J, Sabah N, Gladstone RA, et al. MicroRNA-144 is a circulating effector of remote ischemic preconditioning. Basic Res Cardiol. 2014;109:423.CrossRefPubMed
37.
Li K, Lin T, Chen L, Wang N. MicroRNA-93 elevation after myocardial infarction is cardiac protective. Med Hypotheses. 2017;106:23–5.CrossRefPubMed
38.
Li X, Dai Y, Yan S, Shi Y, Han B, Li J, et al. Down-regulation of lncRNA KCNQ1OT1 protects against myocardial ischemia/reperfusion injury following acute myocardial infarction. Biochem Biophys Res Commun. 2017;491:1026–33.CrossRefPubMed
39.
Li J, Cai SX, He Q, Zhang H, Friedberg D, Wang F, et al. Intravenous miR-144 reduces left ventricular remodeling after myocardial infarction. Basic Res Cardiol. 2018;113:36.CrossRefPubMed
40.
Liu X, Dong Y, Chen S, Zhang G, Zhang M, Gong Y, et al. Circulating MicroRNA-146a and MicroRNA-21 predict left ventricular remodeling after ST-elevation myocardial infarction. Cardiology. 2015;132:233–41.CrossRefPubMed
41.
Lorenzen JM, Batkai S, Thum T. Regulation of cardiac and renal ischemia–reperfusion injury by microRNAs. Free Radic Biol Med. 2013;64:78–84.CrossRefPubMed
42.
Lu C, Wang X, Ha T, Hu Y, Liu L, Zhang X, et al. Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signaling. J Mol Cell Cardiol. 2015;89:87–97.CrossRefPubMedPubMedCentral
43.
Martinez EC, Lilyanna S, Wang P, Vardy LA, Jiang X, Armugam A, et al. MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease. J Mol Cell Cardiol. 2017;112:27–39.CrossRefPubMed
44.
Mathiyalagan P, Sahoo S. Exosomes-based gene therapy for MicroRNA delivery. In: Ishikawa K, editor. Cardiac gene therapy: methods and protocols. New York: Springer; 2017. p. 139–52.CrossRef
45.
Meloni M, Marchetti M, Garner K, Littlejohns B, Sala-Newby G, Xenophontos N, et al. Local inhibition of MicroRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol Ther. 2013;21:1390–402.CrossRefPubMedPubMedCentral
46.
Menees DS, Peterson ED, Wang Y, Curtis JP, Messenger JC, Rumsfeld JS, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med. 2013;369:901–9.CrossRefPubMed
47.
Ong S-B, Katwadi K, Kwek X-Y, Ismail NI, Chinda K, Ong S-G, et al. Non-coding RNAs as therapeutic targets for preventing myocardial ischemia-reperfusion injury. Expert Opin Ther Targets. 2018;22:247–61.CrossRefPubMed
48.
Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation. 2012;126:840–50.CrossRefPubMed
49.
50.
Qiu G, Zheng G, Ge M, Wang J, Huang R, Shu Q, et al. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs. Stem Cell Res Ther. 2018;9:320.CrossRefPubMedPubMedCentral
51.
Salgado-Somoza A, Zhang L, Vausort M, Devaux Y. The circular RNA MICRA for risk stratification after myocardial infarction. IJC Heart Vasc. 2017;17:33–6.CrossRef
52.
Shi J, Bei Y, Kong X, Liu X, Lei Z, Xu T, et al. miR-17-3p contributes to exercise-induced cardiac growth and protects against myocardial ischemia-reperfusion injury. Theranostics. 2017;7:664–76.CrossRefPubMedPubMedCentral
53.
54.
55.
Stokfisz K, Ledakowicz-Polak A, Zagorski M, Zielinska M. Ischaemic preconditioning – current knowledge and potential future applications after 30 years of experience. Adv Med Sci. 2017;62:307–16.CrossRefPubMed
56.
57.
58.
van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci. 2008;105:13027–32.CrossRefPubMedPubMedCentral
59.
60.
Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res. 2014;115:668–77.CrossRefPubMed
61.
Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261–71.CrossRefPubMedPubMedCentral
62.
Wang X, Zhang X, Ren X-P, Chen J, Liu H, Yang J, et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation. 2010;122:1308–18.CrossRefPubMedPubMedCentral
63.
Wang J, Huang W, Xu R, Nie Y, Cao X, Meng J, et al. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med. 2012;16:2150–60.CrossRefPubMedPubMedCentral
64.
Wang X, Zhu H, Zhang X, Liu Y, Chen J, Medvedovic M, et al. Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1. Cardiovasc Res. 2012;94:379–90.CrossRefPubMedPubMedCentral
65.
Wang K, Long B, Zhou L-Y, Liu F, Zhou Q-Y, Liu C-Y, et al. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun. 2014;5:3596.CrossRefPubMed
66.
Wang K, Sun T, Li N, Wang Y, Wang J-X, Zhou L-Y, et al. MDRL lncRNA regulates the processing of miR-484 primary transcript by targeting miR-361. PLoS Genet. 2014;10:e1004467.CrossRefPubMedPubMedCentral
67.
Wang JX, Zhang XJ, Li Q, Wang K, Wang Y, Jiao JQ, et al. MicroRNA-103/107 regulate programmed necrosis and myocardial ischemia/reperfusion injury through targeting FADD. Circ Res. 2015;117:352–63.CrossRefPubMed
68.
Wang K, Liu C-Y, Zhou L-Y, Wang J-X, Wang M, Zhao B, et al. APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat Commun. 2015;6:6779.CrossRefPubMed
69.
Wang K, Liu F, Liu C-Y, An T, Zhang J, Zhou L-Y, et al. The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873. Cell Death Differ. 2016;23:1394–405.CrossRefPubMedPubMedCentral
70.
Wang K, Gan T-Y, Li N, Liu C-Y, Zhou L-Y, Gao J-N, et al. Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. Cell Death Differ. 2017;24:1111–20.CrossRefPubMedPubMedCentral
71.
Wu H-Y, Wu J-L, Ni Z-L. Overexpression of microRNA-202-3p protects against myocardial ischemia-reperfusion injury through activation of TGF-β1/Smads signaling pathway by targeting TRPM6. Cell Cycle. 2019;18:621–37.CrossRefPubMedPubMedCentral
72.
Xiao Y, Zhang Y, Chen Y, Li J, Zhang Z, Sun Y, et al. Inhibition of microRNA-9-5p protects against cardiac remodeling following myocardial infarction in mice. Hum Gene Ther. 2018;30:286–301.CrossRefPubMed
73.
Xu H, Cao H, Zhu G, Liu S, Li H. Overexpression of microRNA-145 protects against rat myocardial infarction through targeting PDCD4. Am J Transl Res. 2017;9:5003–11.PubMedPubMedCentral
74.
Yamamura S, Sumida MI, Tanaka Y. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2018;75:467–84.CrossRefPubMed
75.
Yan Y, Zhang B, Liu N, Qi C, Xiao Y, Tian X, et al. Circulating long noncoding RNA UCA1 as a novel biomarker of acute myocardial infarction. Biomed Res Int. 2016;2016:1–7.
76.
Yang L, Wang B, Zhou Q, Wang Y, Liu X, Liu Z, et al. MicroRNA-21 prevents excessive inflammation and cardiac dysfunction after myocardial infarction through targeting KBTBD7. Cell Death Dis. 2018;9:769.CrossRefPubMedPubMedCentral
77.
Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-γ agonist protects against myocardial ischaemia–reperfusion injury. Cardiovasc Res. 2010;87:535–44.CrossRefPubMed
78.
Ye Y, Perez-Polo JR, Qian J, Birnbaum Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics. 2011;43:534–42.CrossRefPubMed
79.
80.
Zhou L-Y, Zhai M, Huang Y, Xu S, An T, Wang Y-H, et al. The circular RNA ACR attenuates myocardial ischemia/reperfusion injury by suppressing autophagy via modulation of the Pink1/FAM65B pathway. Cell Death Differ. 2018;26:1299–315.CrossRefPubMedPubMedCentral
81.
Zhu H, Fan G-C. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res. 2012;94:284–92.CrossRefPubMed
Metadata
Title
The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury
Authors
Vince Siebert
Joseph Allencherril
Yumei Ye
Xander H. T. Wehrens
Yochai Birnbaum
Publication date
01-08-2019
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 4/2019
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-019-06893-x

Other articles of this Issue 4/2019

Cardiovascular Drugs and Therapy 4/2019 Go to the issue

ORIGINAL ARTICLE

Effect of a Therapeutic Strategy Guided by Lung Ultrasound on 6-Month Outcomes in Patients with Heart Failure: Randomized, Multicenter Trial (EPICC Study)

ORIGINAL ARTICLE

Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease

ORIGINAL ARTICLE

Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients

ORIGINAL ARTICLE

Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial

ORIGINAL ARTICLE

Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis

LETTER TO THE EDITOR

After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits